From r-help-bounces@stat.math.ethz.ch  Fri Jun  8 13:14:02 2007
Return-Path: <r-help-bounces@stat.math.ethz.ch>
Received: from hypatia.math.ethz.ch (hypatia.math.ethz.ch [129.132.145.15])
	by flax9.uwaterloo.ca (8.12.8/8.12.5) with ESMTP id l58HE0hB017935
	for <ktwarwic@flax9.uwaterloo.ca>; Fri, 8 Jun 2007 13:14:01 -0400
Received: from hypatia.math.ethz.ch (hypatia [129.132.145.15])
	by hypatia.math.ethz.ch (8.13.6/8.13.6) with ESMTP id l58HBW6J007320;
	Fri, 8 Jun 2007 19:11:40 +0200
X-Spam-Checker-Version: SpamAssassin 3.2.0 (2007-05-01) on hypatia.math.ethz.ch
X-Spam-Level: 
X-Spam-Status: No, score=0.7 required=5.0 tests=AWL, BAYES_50,
	DKIM_POLICY_SIGNSOME, FH_HOST_EQ_D_D_D_D,
	RDNS_DYNAMIC autolearn=no version=3.2.0
Received: from osrmail (h-68-166-170-51.mclnva23.covad.net [68.166.170.51])
	by hypatia.math.ethz.ch (8.13.6/8.13.6) with ESMTP id l58H8teH006621
	for <r-help@stat.math.ethz.ch>; Fri, 8 Jun 2007 19:08:55 +0200
Received: from [1.254.87.76] (127.0.0.1)
	by localhost (127.0.0.1) with [XMail 0.74 (Win32/Ix86) ESMTP Server]
	id <S16D8C> for <r-help@stat.math.ethz.ch> from
	<f.harrell@vanderbilt.edu>; Fri, 08 Jun 2007 09:47:55 -0000
Message-ID: <46698D21.7050001@vanderbilt.edu>
Date: Fri, 08 Jun 2007 12:08:49 -0500
From: Frank E Harrell Jr <f.harrell@vanderbilt.edu>
User-Agent: Thunderbird 1.5.0.10 (X11/20070403)
MIME-Version: 1.0
To: Bert Gunter <gunter.berton@gene.com>
References: <003301c7a9e6$b1778200$4d908980@gne.windows.gene.com>
In-Reply-To: <003301c7a9e6$b1778200$4d908980@gne.windows.gene.com>
X-Virus-Scanned: by amavisd-new at stat.math.ethz.ch
Cc: "'Giovanni Parrinello'" <parrinel@med.unibs.it>, r-help@stat.math.ethz.ch
Subject: Re: [R] "R is not a validated software package.."
X-BeenThere: r-help@stat.math.ethz.ch
X-Mailman-Version: 2.1.9
Precedence: list
List-Id: "Main R Mailing List: Primary help" <r-help.stat.math.ethz.ch>
List-Unsubscribe: <https://stat.ethz.ch/mailman/listinfo/r-help>,
	<mailto:r-help-request@stat.math.ethz.ch?subject=unsubscribe>
List-Archive: <https://stat.ethz.ch/pipermail/r-help>
List-Post: <mailto:r-help@stat.math.ethz.ch>
List-Help: <mailto:r-help-request@stat.math.ethz.ch?subject=help>
List-Subscribe: <https://stat.ethz.ch/mailman/listinfo/r-help>,
	<mailto:r-help-request@stat.math.ethz.ch?subject=subscribe>
Content-Type: text/plain; charset="us-ascii"
Content-Transfer-Encoding: 7bit
Sender: r-help-bounces@stat.math.ethz.ch
Errors-To: r-help-bounces@stat.math.ethz.ch

Bert Gunter wrote:
> Frank et. al:
> 
> I believe this is a bit too facile. 21 CFR Part 11 does necessitate a
> software validation **process** -- but this process does not require any

For database software and for medical devices -

> particular software. Rather, it requires that those using whatever software
> demonstrate to the FDA's satisfaction that the software does what it's
> supposed to do appropriately. This includes a lot more than assuring, say,
> the numerical accuracy of computations; I think it also requires
> demonstration that the data are "secure," that it is properly transferred
> from one source to another, etc. I assume that the statistical validation of
> R would be relatively simple, as R already has an extensive test suite, and
> it would simply be a matter of providing that test suite info. A bit more
> might be required, but I don't think it's such a big deal. 
> 
> I think Wensui Liu's characterization of clinical statisticians as having a
> mentality "related to job security" is a canard. Although I work in
> nonclinical, my observation is that clinical statistics is complex and
> difficult, not only because of many challenging statistical issues, but also
> because of the labyrinthian complexities of the regulated and extremely
> costly environment in which they work. It is certainly a job that I could
> not do.
> 
> That said, probably the greatest obstacle to change from SAS is neither
> obstinacy nor ignorance, but rather inertia: pharmaceutical companies have
> over the decades made a huge investment in SAS infrastructure to support the
> collection, organization, analysis, and submission of data for clinical
> trials. To convert this to anything else would be a herculean task involving
> huge expense, risk, and resources. R, S-Plus (and much else -- e.g. numerous
> "unvalidated" data mining software packages) are routinely used by clinical
> statisticians to better understand their data and for "exploratory" analyses
> that are used to supplement official analyses (e.g. for trying to justify
> collection of tissue samples or a pivotal study in a patient subpopulation).
> But it is difficult for me to see how one could make a business case to
> change clinical trial analysis software infrastructure from SAS to S-Plus,
> SPSS, or anything else.

What I would love to have is some efficiency estimates for SAS macro 
programming as done in pharma vs. using a high-level language.  My bias 
is that SAS macro programming, which costs companies more than SAS 
licenses, is incredibly inefficient.

Frank

> 
> **DISCLAINMER** 
> My opinions only. They do not in any way represent the view of my company or
> its employees.
> 
> 
> Bert Gunter
> Genentech Nonclinical Statistics
> South San Francisco, CA 94404
> 650-467-7374
> 
> 
> -----Original Message-----
> From: r-help-bounces@stat.math.ethz.ch
> [mailto:r-help-bounces@stat.math.ethz.ch] On Behalf Of Frank E Harrell Jr
> Sent: Friday, June 08, 2007 7:45 AM
> To: Giovanni Parrinello
> Cc: r-help@stat.math.ethz.ch
> Subject: Re: [R] "R is not a validated software package.."
> 
> Giovanni Parrinello wrote:
>> Dear All,
>> discussing with a statistician of a pharmaceutical company I received 
>> this answer about the statistical package that I have planned to use:
>>
>> As R is not a validated software package, we would like to ask if it 
>> would rather be possible for you to use SAS, SPSS or another approved 
>> statistical software system.
>>
>> Could someone suggest me a 'polite' answer?
>> TIA
>> Giovanni
>>
> 
> Search the archives and you'll find a LOT of responses.
> 
> Briefly, in my view there are no requirements, just some pharma 
> companies that think there are.  FDA is required to accepted all 
> submissions, and they get some where only Excel was used, or Minitab, 
> and lots more.  There is a session on this at the upcoming R 
> International Users Meeting in Iowa in August.  The session will include 
> dicussions of federal regulation compliance for R, for those users who 
> feel that such compliance is actually needed.
> 
> Frank
> 


-- 
Frank E Harrell Jr   Professor and Chair           School of Medicine
                      Department of Biostatistics   Vanderbilt University

______________________________________________
R-help@stat.math.ethz.ch mailing list
https://stat.ethz.ch/mailman/listinfo/r-help
PLEASE do read the posting guide http://www.R-project.org/posting-guide.html
and provide commented, minimal, self-contained, reproducible code.

